Author pages are created from data sourced from our academic publisher partnerships and public sources.
Sedation in the intensive care unit with remifentanil/propofol versus midazolam/fentanyl: a randomised, open-label, pharmacoeconomic trial
IntroductionRemifentanil is an opioid with a unique pharmacokinetic profile. Its organ-independent elimination and short context-sensitive half time of 3 to 4 minutes lead to a highly predictable… Expand
Early Treatment of a Migraine Attack while Pain is Still Mild Increases the Efficacy of Sumatriptan
- J. Scholpp, R. Schellenberg, B. Moeckesch, N. Banik
- Cephalalgia : an international journal of…
- 1 November 2004
To investigate the hypothesis that early treatment of a migraine attack with sumatriptan, while pain is still mild, results in higher pain free rates in comparison to delayed treatment, when pain is… Expand
Lipid peroxidation early after brain injury.
The role of lipid peroxidation after brain injury is still not completely understood, and results of different studies have been equivocal. In this study, three proposed peroxidation markers were… Expand
Evaluation of markers of deep vein thrombosis in patients undergoing surgery for maxillofacial malignancies.
- H. Wendel, J. Scholpp, H. Schulze, W. Heller, N. Schwenzer
- Journal of cranio-maxillo-facial surgery…
- 1 August 1999
During and following significant surgical intervention, deep venous thrombosis prophylaxis by application of anticoagulants is routinely used. However, patients with malignant disorders are subject… Expand
Combining Proof-of-Concept With Dose-Finding: Utilization of Adaptive Designs in Migraine Clinical Trials
There is an obvious need to improve clinical trial designs with respect to efficiency, duration and the number of patients recruited. Adaptive (flexible) designs may be valuable in this respect. We… Expand
A Thorough QT Study of Teduglutide in Healthy Subjects
- M. Hartmann, W. Timmer, +5 authors J. Scholpp
- Clinical pharmacology in drug development
- 1 April 2012
Teduglutide, an analog of the endogenous hormone glucagon‐like peptide‐2, is currently being developed for the treatment of short bowel syndrome. This study investigated the potential effects of… Expand